[Humoral and cell mediated immunity induced by HBV-S gene recombinant retroviral vector].
OBJECTIVE
To investigate the effectiveness of recombined retrovirus vector in gene therapy.


METHODS
The retroviral vector PLXSN-S was constructed and transferred into PA317 by means of electroporation, then HepG2, P815, and EL4 cells were infected with the pseudovirus produced from PA317. In the meantime the gene immunization of PLXSN-S was also studied.


RESULTS
HBsAg was expressed variously in the eukaryotic cells mentioned above and successfully evoked antibody response and CTL response to HBsAg after gene immunization.


CONCLUSIONS
Intramuscular DNA immunization represents an efficient technique for priming CTL and antibody response to HBsAg. PLXSN may be used as an effective vector to carry genes of interest to target cells and immunization with it's DNA vaccine might be clinically useful for gene therapy.
Zhou
Z
Z
Institute for Viral Hepatitis, Chongqing University of Medical Sciences.
Zhang
D
D
Ren
H
H
D015316:Genetic Therapy; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000096:biosynthesis / Q000235:genetics*; D006515:Hepatitis B virus / Q000235:genetics* / Q000276:immunology; D007114:Immunization; D011994:Recombinant Proteins / Q000276:immunology; D012190:Retroviridae / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic